Clinical trials: Liraglutide
- Drug or intervention Liraglutide
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral…
- Trial name
- DUAL™ I China (NCT03172494)
- Testing
- Insulin degludec/liraglutide, Insulin degludec, Liraglutide
- Where
- 36 sites in China
- Volunteers
- 720 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate…
- Trial name
- LIRA-SWITCH™ (NCT01907854)
- Testing
- liraglutide, sitagliptin
- Where
- 106 sites in United States, Canada and 5 more
- Volunteers
- 407 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously…
- Trial name
- DUAL™ (NCT02100475)
- Testing
- insulin degludec/liraglutide, insulin aspart
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes…
- Trial name
- DUAL™ II Japan (NCT02911948)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 38 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Novo Nordisk A/S
Obesity
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.
- Trial name
- NCT03041792
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Obesity
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
- Trial name
- NCT03757130
- Testing
- AMG 598, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Diabetes, Diabetes Mellitus, Type 2
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on…
- Trial name
- NCT02964247
- Testing
- liraglutide
- Where
- 82 sites in United States, Brazil and 5 more
- Volunteers
- 303 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ I Japan (NCT02607306)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 76 sites in Japan
- Volunteers
- 819 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes…
- Trial name
- NCT02443155
- Testing
- NNC0114-0006, liraglutide
- Where
- 108 sites in United States, Austria and 16 more
- Volunteers
- 308 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist…
- Trial name
- SCALE™ IBT (NCT02963935)
- Testing
- liraglutide, CMS Intensive Behavior Therapy
- Where
- 10 sites in United States
- Volunteers
- 282 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with…
- Trial name
- NCT01272232
- Testing
- liraglutide
- Where
- 161 sites in United States, France and 11 more
- Volunteers
- 846 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
- Trial name
- SCALE™ Insulin (NCT02963922)
- Testing
- Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 5 more
- Volunteers
- 396 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi
Metabolism and Nutrition Disorder, Obesity
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of…
- Trial name
- NCT00422058
- Testing
- liraglutide, orlistat
- Where
- 19 sites in Belgium, Czechia and 6 more
- Volunteers
- 564 people
- Sponsor
- Novo Nordisk A/S
Obesity
To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes
This study is the first administration of GSK2890457 in humans. The study will be conducted in 3 parts: - Part A (conducted at a single investigative site) will determine the safety and tolerability of GSK2890457 alone in healthy…
- Trial name
- NCT01725126
- Testing
- GSK2890457, Metformin, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve…
- Trial name
- DUAL™ VIII (NCT02501161)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 143 sites in United States, Argentina and 14 more
- Volunteers
- 1,012 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs.
- Trial name
- LIRA-PRIME (NCT02730377)
- Testing
- liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors
- Where
- 232 sites in United States, Canada and 8 more
- Volunteers
- 1,991 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
This trial is conducted in Europe, North America and the United States of America. The aim of this trial is to compare two different titration algorithms of insulin degludec/liraglutide.
- Trial name
- DUAL™ VI (NCT02298192)
- Testing
- insulin degludec/liraglutide
- Where
- 84 sites in United States, Austria and 7 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S